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The aim of the study was to describe clinical effectiveness of azithromycin in
the management of upper respiratory tract infections, to examine the duration of
symptoms after beginning of therapy and to mark possible adverse events of
azithromycin treatment. The overall intention-to-treat (ITT) study population
included 422 patients: 184 with diagnosis of acute pharyngitis (AP), 156 with
acute sinusitis (AS) and 82 with acute otitis media (AOM). Clinical effective-
ness was based on the results of clinical improvement and cure after three day
treatment with azithromycin, calculating the clinical score for each diagnosis
before treatment (at the inclusion), at the 4th day (end of the therapy) and at the
12th (end of the study). In this study azithromycin led to the relief of symptoms
after three days in the 93.6 % of patients. Antibiotics were prescribed within one
year before inclusion in 56.6 % of patients and 20.5 % were previously treated
with macrolides. Clinical effectiveness in ITT population was 95.6 % and there
were 4.4 % failures. Overall, 38 (9.1 %) patients reported 48 adverse events. The
most common were: abdominal pain reported in 14 (1.1 %) patients, diarrhea in
12 (0.9 %), nausea in 5 (0.4 %), vomiting in 5 (0.4 %). The therapy was with-
drawn because of an adverse event in one patient. The results of our study show
that azithromycin in the treatment of upper respiratory tract infections has a high
clinical effectiveness and small number of adverse events. Azithromycin is a re-
liable antibiotic treatment in upper respiratory tract infections, giving fast reso-
lution of symptoms with little adverse events in patients with presumed bacteri-
al infections.
U~inkovitost i sigurnost azitromicina u lije~enju infekcija gornjeg dijela
di{nog sustava
Znanstveni rad
Cilj studije bio je opisati klini~ku u~inkovitost azitromicina u lije~enju infekci-
ja gornjeg dijela di{nog sustava, ispitati duljinu simptoma nakon po~etka terapi-
je i pokazati mogu}e nuspojave lije~enja azitromicinom. U studiju je uklju~no
422 ispitanika: 184 s dijagnozom akutnog faringitisa, 156 s dijagnozom akutnog
sinuitisa, te 82 bolesnika s akutnom upalom srednjeg uha. Klini~ka u~inkovitost
nakon tri dana lije~enja azitromicinom temeljila se na pobolj{anju klini~ke slike
i izlje~enju bolesnika. Za svaku dijegnozu je izra~unat klini~ki zbroj prije po~et-
ka lije~enja, te ~etvrti i dvanaesti dan nakon po~etka lije~enja. Studija je pokaza-
la kako je trodnevno lije~enje azitromicinom dovelo do smanjenja simptoma u
93,6 % bolesnika. Godinu dana prije uklju~enja u studiju antibiotici su bili
prethodno propisivani u 56,6 % bolesnika, a 20,5 % bolesnika je bilo lije~eno
makrolidima. Klini~ka u~inkovitost je bila pozitivna u 95,6 % bolesnika, a
neuspjeh lije~enja zabilje`en je u 4,4 % bolesnika. Prijavljeno je 48 nuspojava
kod 38 (9,1 %) bolesnika. Naj~e{}e nuspojave bile su: bol u trbuhu zabilje`ena
kod 14 (1,1 %) bolesnika, proljev kod 12 (0,9 %), mu~nina kod 5 (0,4 %), te
povra}anje kod 5 (0,4 %) bolesnika. Prekid terapije zbog nuspojava zabilje`en
je kod jednog bolesnika. Rezultati studije pokazuju da u lije~enju infekcija
gornjeg di{nog sustava azitromicinom ima visoku u~inkovitost i mali broj nus-
pojava. Azitromicin je pouzdan lijek izbora u lije~enju infekcija gornjeg dijela
di{nog sustava, s brzim povla~enjem simptoma infektivne bolesti i relativno
malim brojem nuspojava. 
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2008 and the last in November 2009). Last patient finished
the study in December 2009. 
The study protocol was reviewed and approved by
Ethics Committees (EC) in Croatia, Bosnia and Herzego-
vina and Macedonia. Each patient or patient's parent/legal
guardian signed Informed Consent Form before inclusion.
Only patients with clinical signs and symptoms of acute
pharyngitis/tonsilitis, acute sinusitis and acute otitis media
to whom azithromycin would be prescribed regardless of
their participation in this study were considered for inclu-
sion. Inclusion criteria for acute pharyngitis, acute sinusi-
tis and acute otitis media are listed in Table 1. Patients with
any of the above diagnoses were treated with azithromycin
500 mg tablets or oral suspension for 3 days. Children
weight less than 50 kg received 10 mg/kg/day for 3 days in
oral suspension.
Azithromycin 500 mg tablets or oral suspension for
children for the purpose of the study was provided by
Study Sponsor. 
At Visit 1 full medical history and clinical examination
of patients with AP, AS and AOM were done. Optionally
hematological tests and throat swabs were collected. Each
patient received Patient's Diary in which they had to record
time of azithromycin administration over 3 days, body
temperature (twice daily), any adverse events, time when
they felt relief of signs and symptoms (after one day, two
days, or after more than three days). Follow up visits were
at days 4 and 12. They were asked to bring filled diaries at
visit 2. 
Patients were clinically examined. General and specif-
ic clinical signs and symptoms were recorded, as well as
adverse events. Clinical score was calculated for each di-
agnosis as presented in Table 2. The sum of all scores gave
a total clinical score (TCS) which was considered as a
measure for clinical findings at each visit. Maximum score
for AP was 19 and for AS and AOM was 15.
Clinical response to therapy was evaluated as cure
(complete disappearance of signs and symptoms present at
Visit 1), improvement (deffervescence with substantial re-
duction in the intensity of signs and symptoms present at
Visit 1; no need for additional antimicrobial therapy), fail-
ure (progression or recurrence of signs and symptoms and
introduction of other antimicrobial therapy) or not-evalu-
able. 
Adverse events (AE) were recorded at all post-baseline
visits in patient's case report form (CRF). AE is any unfa-
vorable and unintended sign, symptom or disease tempo-
rally associated with the use of a medicinal product,
whether or not it is related. AE-report period began upon
subject's entry into the study, defined as the time at which
the informed consent was obtained, and ended at the final
visit. All serious adverse events (SAEs) were reported in
accordance with the local regulatory requirements. The
outcome of an AE was also recorded. 
Introduction
Upper-respiratory tract infections such as acute pha-
ryngitis/tonsillitis (AP), acute sinusitis (AS) and acute oti-
tis media (AOM) are common in children and adults.
These infections are usually mild, allowing treatment on
outpatient basis [1–3]. Although viruses account for most
of these infections, bacterial primary infection or superin-
fection may require antibiotic treatment. Most common
bacterial causes include group A beta-hemolytic strepto-
coccus, Streptococcus pneumoniae, Haemophilus influen-
zae and Moraxella catarrhalis [1–3]. AOM is the most
common in earlier childhood. By 3 years of age more than
two thirds of children have had one or more episodes of
acute otitis media, and one third have had three or more
episodes [2]. AP is usually disease of children and young
adults, with approximately 50 % of cases diagnosed in pa-
tients between 5 and 24 years of age [1]. 
Azithromycin is a macrolide antibiotic structurally
modified from erythromycin with an expanded spectrum
of activity and improved tissue pharmacokinetic charac-
teristics relative to erythromycin [4]. It has expanded and
enhanced antibacterial activity: it is particularly active
against gram-negative pathogens, such as H. influenzae
and M. catarrhalis [4, 5]. Azithromycin is also active
against atypical pathogens such as Mycoplasma pneumo-
niae and Chlamydophila pneumoniae, which can also be a
cause of acute pharyngitis. In the last 20 years resistance of
bacteria causing respiratory tract infections increased, es-
pecially strains of S. pneumoniae, but reports on how that
affects the results of the treatment are scarce and contro-
versial [4–6]. Azithromycin also achieves prolonged and
higher tissue concentrations and has a low incidence of
gastrointestinal side effects compared to similar antibi-
otics [4, 7, 8]. Competitive advantages of azithromycin
over other known antibiotics are its short dosing period
and low potential for adverse drug reactions [4, 7, 9]. In
clinical trials azithromycin showed to be either better or
equally well tolerated, compared to other antibiotics
[9–20].
The present study describes clinical effectiveness of
azithromycin in management of upper respiratory tract in-
fections, examines duration of symptoms after beginning
the therapy and possible adverse events of treatment with
azithromycin.
Patients and Methods
This was international, multicenter, non-comparative
study, which was conducted in centers in Croatia, Bosnia
and Herzegovina and Macedonia. Outpatients were en-
rolled in this study by primary care physicians during the
period of 19 months (first patient was enrolled in June
Azithromycin in upper respiratory tract infections
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Statistics 
Categorical data were expressed in frequencies and
relevant percentage. The significance of the observed dif-
ferences in frequencies between relevant subgroups was
tested with chi-square test or Fisher's exact test when ap-
propriate. For continuous variables we calculated mean
values with standard deviations. Differences between sub-
groups of interest were tested with Wilcoxon rank-sum
test. The primary outcome variable were effectiveness and
tolerability expressed as the number (percentage) of cured
patients and number (percentage) of patients with adverse
drug reactions (ADR). Secondary outcome variable was
regression of symptoms assessed by changes of total clini-
cal score. Missing values of longitudinal variables which
describe treatment effectiveness (presence or absence of
symptoms or accompanying scores) were imputed follow-
ing the last observation carried forward (LOCF) to avoid
the bias of false positive results and preserve the power of
the study. Generalized linear mixed effects model was
used to assess factors independently influencing regres-
sion of clinical score. Effectiveness analysis was carried
out on ITT population (patients who have taken at least one
dose of azithromycin and were present at least at one post-
baseline visit). Safety data were analyzed on the safety
population (confirmed taking of at least one azithromycin
dose). All analyses were performed using SAS for Win-
dows, version 9.2. SAS Institute Inc.
ACUTE PHARYNGITIS/TONSILLITIS (AP)
– inclusion criteria
– Male or female out-patients;
– Acute onset of disease indicated by presence of fever (>37° C)
– Presence of at least 2 specific clinical signs and symptoms such as: sore throat, pharyngeal erythema, tonsillar enlargement, ton-
sillopharyngeal exudates and painful cervical lymphadenopathy;
– Signed informed consent (for minors, parent or legal guardian written consent needs to be obtained).
ACUTE SINUSITIS (AS)
– inclusion criteria
– Male or female out-patients;
– Presence of at least 2 specific clinical signs and symptoms such as: nasal discharge, nasal congestion and facial tenderness;
– Presence of signs and symptoms for at least 7 days, but less than 28 days (mild to moderate cases);
– Signed informed consent (for minors, parent or legal guardian written consent needs to be obtained).
ACUTE OTITIS MEDIA (AOM)
– inclusion criteria
– Male or female out-patients;
– Acute onset of disease indicated by presence of fever (>37° C)
– Presence of middle ear effusion (MEE) indicated by any of the following: bulging of the tympanic membrane, limited or absent
mobility of the tympanic membrane, air-fluid level behind the tympanic membrane, otorrhea
– Signs and symptoms of middle ear inflammation as indicated by either: distinct erythema of the tympanic membrane or, distinct
otalgia or irritability (discomfort clearly referable to the ear[s] that results in interference with or precludes normal activity or
sleep)
– Signed informed consent (for minors, parent or legal guardian written consent needs to be obtained).
– exclusion criteria
– "No" as answer to any of inclusion criteria
– Hypersensitivity to macrolides
– Treatment with any antibiotic within 14 days prior to enrollment
– Participation in any clinical study within 4 weeks prior to enrollment
– Prior enrollment in this study
– Tachypnea (> 20 breaths/min for adults, or more than two standard deviations appropriate for the age of the child)
+ FOR AOM:
– Signs and symptoms of any complication of AOM
– Tympanostomy tubes present
– Otitis externa
Table 1. Inclusion and exclusion criteria
Tablica 1. Uklju~ni i isklju~ni kriteriji
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Results
Overall 422 ITT patients with URTI were included into
the study (184 acute pharyngitis, 156 acute sinusitis, 82
acute otitis media). 
Acute Pharyngitis
Of 187 patients with acute pharyngitis, 184 satisfied
criteria for ITT analysis. Demographic clinical and base-
line data are presented in Table 3. 
Pharyngeal swab was taken in only 52 (32.6 %) pa-
tients. Group A beta-hemolytic streptococcus (GABHS)
was isolated in only 12/52 patients. Nevertheless, our data
enable us to evaluate presence of four Centor criteria sug-
gesting streptococcal pharyngitis or at least require micro-
biological confirmation of streptococcal disease (fever
>38 °C, painful angular lymphadenopathy, presence of
tonsillar/pharyngeal exudates and absence of cough).
From 184 patients 25.5 % had positive all four Centor cri-
teria, 33.6 % had 3 positive criteria, 28.2 % had two and
12.5 % had only one positive Centor criteria. 
Total clinical score based on the intensity of symptoms
and signs of acute pharyngitis were calculated for each pa-
tient. The score ranged betwee n 5 and 17, median 12. In
75 % of patients it was bellow or equal 14 suggesting over-
all moderate intensity of symptoms. 
Antibiotics within one year before inclusion were tak-
en by 99 (53.8 %) patients. Median time of taking antibi-
otics before inclusion was 4.5 months. Macrolides were
taken by 37 (20.1 %) patients. Median time of taking any
macrolide was 7.0 months.
GENERAL CLINICAL SIGNS AND SYMPTOMS
Fever (daily peak) 0-Absent 1 – (37,1–38° C) 2 – (38,1–39° C) 3 – (>39°C)
Chills 0 – Absent 1 – Present
Headache 0 – Absent 1 – Present
Cough 0 – Absent 1 – Present
Rhinitis (Except for AS) 0 – Absent 1 – Present
Vomiting 0 – Absent 1 – Present
Inappetence 0 – Absent 1 – Present
SPECIFIC CLINICAL SIGNS AND SYMPTOMS
ACUTE PHARYNGITIS
Sore throat 0 – Absent 2 – Present
Pharyngeal erythema 0 – Absent 2 – Present
Tonsillar enlargement 0 – Absent 2 – Present
Tonsillopharyngeal exudates 0 – Absent 2 – Present
Painful cervical lymphadenopathy 0 – Absent 2 – Present
ACUTE SINUSITIS
Nasal discharge 0 – Absent 1 – Serous 2 – Seromucous 3 – Mucopurulent
Nasal congestion 0 – Absent 2 – Present
Facial tenderness 0 – Absent 2 – Present
ACUTE OTITIS
Bulging of tympanic membrane 0 – Absent 1 – Present
Limited or absent mobility of tympanic
membrane
0 – Absent 1 – Present
Otalgia or irritability 0 – Absent 1 – Present
Purulent otorrhea 0 – Absent 1 – Present
Air-fluid level behind the tympanic 
membrane 0 – Absent 1 – Present
Erythema of the tympanic membrane 0 – Absent 1 – Present
Table 2. Clinical score used in the assessment of treatment effectiveness
Tablica 2. Klini~ki zbroj kori{ten za procjenu u~inkovitosti lije~enja
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Clinical effectiveness was high with only nine failures
(Table 4). From 184 patients 85.3 % (157/184) were
marked as cure and 9.8 % (18/184) as an improvement, so
there was 95.1 % (175/184) successfully treated patients. 
A significant drop of clinical scores values occurred
within three days of treatment, which can be seen in Figure
1 (p < 0.001). Previous use of macrolides or other antibiot-
ic did not impact regression of signs and symptoms of the
disease (p = 0.419 and p = 0.123, respectively).
Based o microbiology findings 11/12 patients with iso-
lated GABSH at baseline were cured and there was 1 fail-
ure. 
Diaries were received from 180 patients. Figure 2 pre-
sents cumulative percentage of patients reporting relief
from symptoms from the day of inclusion. From 180 pa-
tients 171 had a relief of symptoms within 3 days (Table 4).
Persistence of symptoms after day 3 was assessed in six
patients.
Concomitant therapy was also reported for 108
(58.8 %) patients. Antipyretics (paracetamol with 44.5 %
of all concomitant therapy) were the most commonly taken
drugs, although fever at inclusion was not high.
Acute Sinusitis
All of 156 patients with acute sinusitis satisfied criteria
for ITT analysis. Demographic clinical and baseline data
are presented on table 3. 
Although not defined in Study protocol, the nasal swab
was taken in 8 patients (5.1 %), in 3 patients culture was
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Acute pharyngitis Acute sinusitis Acute otitis media
Overall patients (number) 184 156 82
COUNTRIES
Croatia 103 (56 %) 94 (60.3 %) 46 (56.1 %)
Bosnia and Herzegovina 24 (13 %) 17 (10.9 %) 7 (8.5 %)
Macedonia 57 (31 %) 45 (28.8 %) 29 (35.4 %)
AGE (mean ± SD) 21.4 ± 15.6 28.9 ± 16.2 21.6 ± 18.4
GENDER – Male (%) 83 (45.1 %) 63 (40.4 %) 42 (51.2 %)
HEIGHT (mean ± SD) 151.8 ± 31.8 165.9 ± 16.4 146.5 ± 36.2
WEIGHT (mean ± SD) 54 ± 25.7 65.9 ± 18.4 52.9 ± 29.6
BMI (mean ± SD) 21.5 ± 4.8 23.4 ± 4.2 21.8 ± 5.3
OCCUPATION
Child 79 (42.9 %) 44 (28.2 %) 39 (47.6 %)
Student 26 (14.1 %) 20 (12.8 %) 10 (12.2 %)
Active 75 (40.8 %) 84 (53.8 %) 30 (36.6 %)
Retired 4 (2.2 %) 7 (4.5 %) 3 (3.7 %)
Table 3. Demographic and baseline data
Tablica 3. Demografski i osnovni podaci
Acute pharyngitis Acute sinusitis Acute otitis media
CLINICAL EFFECTIVENESS
Cure 157 (85.3 %) 117 (75 %) 68 (82.9 %)
Improvement 18 (9.8 %) 34 (21.8 %) 10 (12.2 %)
Failure 9 (4.9 %) 5 (3.2 %) 4 (4.9 %)
DAY OF RELIEFAS REPORTED BY PATIENTS 
1 43 (24.2 %) 21 (14.2 %) 20 (25.3 %)
2 70 (39.5 %) 41 (27.8 %) 27 (34.1 %)
3 58 (32.7 %) 68 (46.2 %) 30 (37.9 %)
4 6 (3.3 %) 17 (11.5 %) 2 (2.5 %)
Table 4. Clinical effectiveness and day of relief as reported by patients
Tablica 4. Klini~ka u~inkovitost i dan izlje~enja prema samoprocjeni bolesnika
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positive yielding isolates of S. pneumoniae, H. influenzae
and Staphylococcus aureus in each sample.
Each symptom of acute sinusitis was present in over
90 % of patients. The total clinical score at baseline ranged
between 5.0 and 14.0, median 10.0. In 75 % patients it was
above or equal 11.0, suggesting moderate intensity of
symptoms. 
Antibiotics within one year before inclusion were tak-
en by 84 (53.9 %) patients. Median time of taking antibi-
otics before inclusion was 5.0 months. Macrolides were
taken by 34 (21.8 %) patients, median time of taking be-
fore inclusion was 7.0 months.
Clinical effectiveness was high 96.8 % (151/156) with
only 5 failures (Table 4). 
A significant drop of clinical scores mean values oc-
curred within three days of treatment, p < 0.001 (Figure 1).
Previous use of macrolides or other antibiotic did not im-
pact regression of signs and symptoms of the disease
(p = 0.336 and p = 0.902, respectively).
A total of 147 patients provided information on relief
of symptoms in their Patient's diaries. Relief of all symp-
toms occurred within three days from the start of treatment
in the 88.4 % (130/147) of patients (Figure 2). Persistence
of symptoms after day 3 was assessed in 17 patients (Table
4).
Concomitant therapy was reported for 108 (69.2 %) pa-
tients and antipyretics were the most common concomi-
tant therapy. 
Figure 1. Mean values of calculated clinical score in patients on azithromycin: solid line – acute pharyngitis, dashed line – acute sinusi-
tis and dotted line – acute otitis media
Slika 1. Srednje vrijednosti izra~unatog klini~kog zbroja u bolesnika lije~enih azitromicinom: puna crta – akutni faringitis, isprekidana
crta – akutni sinusitis i to~kasta crta – akutna upala srednjeg uha
Figure 2. Self-reported symptom relief cumulative incidence in patients treated with azithromycin: solid line – acute pharyngitis, dashed
line – acute sinusitis and dotted line – acute otitis media
Slika 2. Kumulativna u~estalost olak{avanja simptoma prema samoprocjeni bolesnika lije~enih azitromicinom:  puna crta – akutni
faringitis, isprekidana crta – akutni sinusitis i to~kasta crta – akutna upala srednjeg uha
Azithromycin in upper respiratory tract infections
Acute Otitis Media
All of 82 patients with acute otitis media satisfied crite-
ria for ITT analysis. Demographic baseline and clinical da-
ta are presented in table 3. 
At the inclusion the total score ranged between 5.0 and
12.0, median 8.0. In 75 % patients it was bellow or equal
9.0 suggesting overall mild to moderate intensity of symp-
toms. 
Antibiotics within one year before inclusion were tak-
en by 61 (62.2 %) patients. Time of taking antibiotics be-
fore inclusion was 3.0 months. Macrolides were taken by
16 (19.5 %) patients. Median time of taking any macrolide
was 7.0 months. Concomitant therapy was reported for 55
(67.0 %) patients. 
Clinical cure or improvement was recorded in 95.1 %
(78/82) of patients (Table 4). 
A significant drop of clinical scores values occurred
within three days of treatment and can be seen in Figure 1
(p < 0.001). Previous use of macrolides or other antibiotic
did not impact regression of signs and symptoms of the
disease (p = 0.557 and p = 0.479, respectively).
In 97.5 % (77/79) patients the relief of all symptoms
occurred in three days (Figure 2). Two patients did not re-
port day of relief. Persistence of symptoms after day 3 was
assessed in two patients (Table 4).
Safety
Safety population includes 422 patients. Overall, 38
(9.1 %) of patients reported 48 adverse events. Thirty one
AEs were characterized as possibly, probably or definitely
related to azithromycin. The most common adverse events
were abdominal pain reported in 14 (1.1 %) patients, diar-
rhea in 12 (0.9 %), nausea in 5 (0.4 %), vomiting in 5
(0.4 %). 
Discussion
In this study azithromycin led to relief of symptoms
afte three days in the majority of patients and the clinical
effect was observed apparently early. The earliest treat-
ment effect was observed with respect to resolution of
fever which in all groups occurred within 48 hours of treat-
ment. Such fast resolution of symptoms can be explained
by pharmacokinetic of azithromycin and fast achievement
of high tissue concentrations (4). The patients in this study
were analyzed as a group. Any division and analysis of
subgroups would be inappropriate because of the low
number of patients. 
All patients that completed study were given full
dosage (3 days of therapy). Further, we observed high
compliance rate (99.5 % in AP, 98.7 % in AS and 100 % in
AOM group), which might also contribute to the good ef-
fectiveness of azithromycin in our study. Other factors
which could contribute to effectiveness of azithromycin
might be the mild to moderate course of the disease in our
patients (based on clinical score) and also possible viral
etiology. However, in all groups clinical scores at the in-
clusion were suggesting overall moderate infection and
the observed clinical effectiveness was high. 
The effectiveness of azithromycin in treatment of acute
pharyngitis remained in the ranges of earlier clinical stud-
ies [9, 10]. However, on contrary to earlier studies, in our
study pharyngeal swab was taken in only 32.6 % (52/184)
patients with AP and streptococcal infection was con-
firmed in 12/52 patients. Therefore, since most of acute
pharyngitis were diagnosed clinically, Centor criteria were
helpful in establishing the possibility of streptococcal
pharyngitis (fever >38 °C, painful angular lymphadenopa-
thy, presence of tonsillar/pharyngeal exudates and absence
of cough). If three or four of Centor criteria were met, the
positive predictive value is 40 to 60 % [11, 12]. In our
study almost 60 % of patients had 3 or 4 positive Centor
criteria. This is in accordance with the observation that
more than 30 % patients in AP group had rhinitis which
suggests viral infection. This can be considered as limita-
tion of our study compared to studies where only microbi-
ologically proven streptococcal pharyngitis was included.
On the other hand, this represents reality of everyday clin-
ical practice in which the culture diagnostic of suspected
bacterial diseases is often optional [9, 10] and the therapy
is given empirically. 
Although the nasal swab is not adequate for confirma-
tion of etiological diagnose it was taken in 5.1 % of pa-
tients, whereas X-ray of paranasal sinuses was performed
in 10.9 % patients representing still every-day practice in
diagnosing AS. Similarly, Andre et al. found that in pa-
tients with acute sinusitis who came to their general practi-
tioner X-ray and ultrasonic investigations were performed
in 1.2 % and 12.1 % of consultations, respectively [13].
These findings again confirm that most of the decisions
about antibiotic treatment in every day clinical setting is
grounded on clinical symptoms, despite of results of meta-
analysis by Engels et al. which showed that useful infor-
mation for diagnosis of sinusitis were provided by radio-
graphy and clinical evaluation, especially risk score [14].
Although some authors consider that antibiotics are
overused in the treatment of AS, which may lead to higher
number of adverse events and development of the resis-
tance. Haye et al. concluded that antibiotics are beneficial
because they may speed recovery in patients with moder-
ate and severe symptoms of suspected sinusitis. Their
comparative study on patients with AS have shown 93 %
of clinical effectiveness in group treated with azithro-
mycin [15] which is similar to the clinical effectiveness
observed in our study. Other comparative studies have also
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shown that azithromycin has clinical effectiveness equal
as comparator [16].
In AOM group about two thirds of patients had signs
and symptoms suggesting bacterial infection such as
bulging of tympanic membrane (92.7 %) or ear discharge
(41.5 %). Azithromycin is known to achieve sustained tis-
sue concentrations in a wide range of body sites, including
middle ear, this could again explain high effectiveness of
azithromycin in AOM group [19, 20]. This is also in accor-
dance with comparative studies which have shown equal
effectiveness of azithromycin to amoxicillin/clavulanate
for management of acute otitis media, with less adverse
events in patients treated with azithromycin [19, 20]. The
majority of patients were adults in whom the etiology of
AOM is similar to children [21].
The dispensing of azithromycin was at the discretion of
physician in patients who would be treated with azi-
thromycin according to existing guidelines anyway[12,
13, 18, 22]. This study was non-comparative post-market-
ing observational study and this can be considered as its
main limitation. However, this study also represents every
day clinical approach to empirical antimicrobial treatment.
Therefore, it provides data on 'real-life' effectiveness of
azithromycin after twenty years of its clinical use.
Results of our study show azithromycin's known clini-
cal effectiveness and favorable safety profile with small
number of adverse events in treatment of upper respiratory
tract infection.. Our conclusion is that azithromycin is a re-
liable antibiotic choice for the treatment of upper respira-
tory tract infections, because of adequate coverage, fast
resolution of symptoms and few adverse events.
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Dubravka, ^a~kovi} Sanja, Tandara Matilda, Amerl-[aki}
Vjekoslava, Varovi} Vi{nja
Macedonia: Clinic of pulmology and allergology Skopje:
Go{eva Zlatica; Institute for children's respiratory diseases
Skopje: Lazarevska Iskra; Primary care: Bilbilovska Branka,
Lakinska-Netkova Roza, Stojanovska Violeta, Mitevski Dragan,
Stanislevic Elica, Naumoska Tina
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